There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Karyopharm Therapeutics (KPTI), Autolus Therapeutics Plc (AUTL) and Trillium Therapeutics (TRIL) with bullish sentiments.
Karyopharm Therapeutics (KPTI)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Karyopharm Therapeutics, with a price target of $29. The company’s shares closed yesterday at $4.69, close to its 52-week low of $3.92.
White commented:
“We base our $29 price target on probability-adjusted revenue forecasts for selinexor. We use a net present value of our revenue forecast through 2026, apply a 50% probability of success (POS) for selinexor in penta-refractory multiple myeloma, a 40% POS for selinexor in combination treatment for multiple myeloma, a 25% POS for selinexor in 25% POS for selinexor in solid tumors. We use a 4x P/S multiple and an estimated early stage pipeline value of $0.35/share. Our P/S multiple of 4x is in-line with Karyopharm’s peers that range between 2-5x.”
According to TipRanks.com, White is a 5-star analyst with an average return of 15.5% and a 49.3% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Aileron Therapeutics Inc.
Currently, the analyst consensus on Karyopharm Therapeutics is a Moderate Buy with an average price target of $13.14.
See today’s analyst top recommended stocks >>
Autolus Therapeutics Plc (AUTL)
Autolus Therapeutics Plc received a Buy rating and a $41 price target from H.C. Wainwright analyst Debjit Chattopadhyay today. The company’s shares closed yesterday at $23.04, close to its 52-week low of $19.17.
Chattopadhyay noted:
“Our $41 target, reduced from $45 previously, is derived from a risk-adjusted, sum-of-the-parts analysis that drives our DCF model, and reflects the recent dilution from the secondary offering. Our DCF is based on: beta of 1.00, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 7.6%, and tax rate of 15% beginning in FY 2027. We value: (1) (3) AUTO 1 and AUTO4 at $3 each, which are derived from probability adjusted peak sales of: (1) $321M for AUTO2; (2) $484M for AUTO3; (3) $69M for AUTO1; and (4) $69M for AUTO4.”
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.0% and a 45.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Mersana Therapeutics Inc.
Autolus Therapeutics Plc has an analyst consensus of Moderate Buy, with a price target consensus of $45.
Trillium Therapeutics (TRIL)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Trillium Therapeutics, with a price target of $4. The company’s shares closed yesterday at $0.66, close to its 52-week low of $0.51.
Ramakanth noted:
“We maintain our Buy rating of TRIL and our 12-month price target of $4.00 per diluted share. We derive our price target based on a risk-adjusted net present value analysis of projected TTI-621 revenues through 2030 assuming a 12% discount rate and a 3% terminal growth rate.”
According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.6% and a 31.7% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
Trillium Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.50, a 279.2% upside from current levels. In a report issued on May 13, Cowen & Co. also assigned a Buy rating to the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
